CG
CTXR icon

Cutler Group’s Citius Pharmaceuticals CTXR Stock Holding History

Cutler Group’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-720
Closed -$24K – 5425
2021
Q4 		$24K Sell
720
-112
-13% -$5.08K ﹤0.01% 2978
2021
Q3 		$23K Buy
832
+388
+87% +$19.5K ﹤0.01% 3212
2021
Q2 		$11K Buy
+444
New +$26.7K ﹤0.01% 3794

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Cutler Group's CTXR Position: Q1 2024 in Review

Cutler Group sold out of Citius Pharmaceuticals (CTXR) in Q1 2024, closing a stake of 1 share.

Cutler Group first reported a position in CTXR in Q2 2021 and held it in 11 quarters. The position peaked at $16K in Q3 2021. 73 funds tracked by Wall St. Rank hold CTXR as of Q1 2024.

  • Cutler Group reported no remaining Citius Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 1 Citius Pharmaceuticals share in Q1 2024.
  • Cutler Group first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 11 quarters.
  • Cutler Group's Citius Pharmaceuticals position peaked at $16K in Q3 2021.
  • 73 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.